MDC and NMD4C Hiring Full-Time Clinical Trials and Community Practice Manager
Muscular Dystrophy Canada is hiring a full-time Clinical Trials and Community of Practice Manager to support our Clinical Trial Network and Community of Practice task groups and help bring clinical trials to Canada!
Join our team of dedicated colleagues and volunteers in breaking down barriers for the neuromuscular community. Work closely with clinicians, NMD4C investigators and members, industry, government, clinical trial Principal Investigators, the Canadian Neuromuscular Disease Registry (CNDR) and the Care and Trial Site Registry (CTSR) in Canada to ensure a coordinated approach to clinical trials.
Read the full job description here!
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.